Perrigo Co. Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IE00BGH1M568
USD
13.49
-0.47 (-3.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Perrigo Co. Plc stock-summary
stock-summary
Perrigo Co. Plc
Pharmaceuticals & Biotechnology
Perrigo Co. Plc engages in providing over-the-counter (OTC) self-care and wellness solutions. Its solutions enhance individual well-being by enabling consumers to proactively prevent or treat conditions that can be self-managed. The Company operates through three segments: Consumer Self-Care Americas, Consumer Self-Care International and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment comprises the store brand consumer self-care business in the United States (U.S.), Mexico and Canada. The Consumer Self-Care International segment includes the branded consumer self-care business in Europe, along with generic consumer-focused businesses in the United Kingdom (U.K.) and Australia. The Prescription Pharmaceuticals segment commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel.
Company Coordinates stock-summary
Company Details
The Sharp Building, Hogan Place , DUBLIN None : D02 TY74
stock-summary
Tel: 353 1 70940001 269 6863373
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 97 Schemes (49.9%)

Foreign Institutions

Held by 153 Foreign Institutions (13.23%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Murray Kessler
President, Chief Executive Officer, Director
Mr. Orlando Ashford
Director
Ms. Katherine Doyle
Director
Mr. Bradley Alford
Independent Director
Mr. Rolf Classon
Independent Director
Ms. Adriana Karaboutis
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,056 Million
(Quarterly Results - Jun 2025)
Net Profit:
0 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,072 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.04%

stock-summary
Debt Equity

0.72

stock-summary
Return on Equity

0.37%

stock-summary
Price to Book

0.69